Jingwei Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7965272/publications.pdf

Version: 2024-02-01

37 papers	761 citations	623734 14 h-index	552781 26 g-index
39 all docs	39 docs citations	39 times ranked	970 citing authors

#	Article	IF	Citations
1	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	3.8	13
2	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.	1.9	23
3	Mechanisms of action of the sodiumâ€glucose cotransporterâ€2 (<scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the <scp>CANVAS</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1950-1956.	4.4	11
4	Worse prognosis in women, compared with men, after thrombolysis: An individual patient data pooling study of Asian acute stroke registries. International Journal of Stroke, 2021, 16, 784-791.	5.9	5
5	Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm. International Journal of Stroke, 2021, 16, 222-228.	5.9	9
6	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. International Journal of Cardiology, 2021, 324, 165-172.	1.7	6
7	Sodiumâ€glucose coâ€transporterâ€2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 252-257.	4.4	12
8	Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus. Metabolism: Clinical and Experimental, 2021, 116, 154509.	3.4	0
9	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	2.7	30
10	Canagliflozin, serum magnesium and cardiovascular outcomesâ€”Analysis from the CANVAS Program. Endocrinology, Diabetes and Metabolism, 2021, 4, e00247.	2.4	5
11	Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2707-2715.	4.4	6
12	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia, 2021, 64, 2147-2158.	6.3	45
13	Association Between Circulating GDFâ€15 and Cardioâ€Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. Journal of the American Heart Association, 2021, 10, e021661.	3.7	16
14	Mediators of the Effects of Canagliflozin on HeartÂFailure in Patients With Type 2 Diabetes. JACC: Heart Failure, 2020, 8, 57-66.	4.1	93
15	Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke. Stroke, 2020, 51, 588-593.	2.0	4
16	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2925-2936.	6.1	82
17	Self-reported Snoring Patterns Predict Stroke Events in High-Risk Patients With OSA. Chest, 2020, 158, 2146-2154.	0.8	21
18	Sex Differences in Disease Profiles, Management, and Outcomes Among People with Atrial Fibrillation After Ischemic Stroke: Aggregated and Individual Participant Data Meta-Analyses. Women S Health Reports, 2020, 1, 190-202.	0.8	5

#	Article	IF	Citations
19	Effects of Canagliflozin on Amino-Terminal Proâ€“B-Type NatriureticÂPeptide. Journal of the American College of Cardiology, 2020, 76, 2076-2085.	2.8	50
20	Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus. Circulation: Heart Failure, 2020, 13, e007054.	3.9	46
21	The function of RNase L and its degradation mechanism in cardiac acute ischemic injury. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 400-411.	4.9	4
22	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International, 2020, 98, 769-777.	5.2	69
23	Reply. JACC: Heart Failure, 2020, 8, 427.	4.1	0
24	Sleep duration and risk of cardiovascular events: The SAVE study. International Journal of Stroke, 2020, 15, 858-865.	5.9	19
25	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. Diabetes, 2020, 69, .	0.6	2
26	1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial. Diabetes, 2020, 69, .	0.6	0
27	1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD). Diabetes, 2020, 69, .	0.6	0
28	1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial. Diabetes, 2020, 69, .	0.6	0
29	Galuteolin attenuates cerebral ischemia/reperfusion injury in rats via anti-apoptotic, anti-oxidant, and anti-inflammatory mechanisms . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2671-2680.	2.2	14
30	Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study. International Journal of Stroke, 2019, 14, 670-677.	5.9	15
31	Sex differences in blood pressure after stroke. Journal of Hypertension, 2019, 37, 1991-1999.	0.5	6
32	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatology, The, 2019, 1, e220-e228.	3.9	38
33	1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. Diabetes, 2019, 68, .	0.6	1
34	Poly(Lactide-Co-Glycolide)-Monomethoxy-Poly-(Polyethylene Glycol) Nanoparticles Loaded with Melatonin Protect Adipose-Derived Stem Cells Transplanted in Infarcted Heart Tissue. Stem Cells, 2018, 36, 540-550.	3.2	44
35	Upregulated ATF6 contributes to chronic intermittent hypoxia-afforded protection against myocardial ischemia/reperfusion injury. International Journal of Molecular Medicine, 2016, 37, 1199-1208.	4.0	13
36	Serum Diamine Oxidase as a Hemorrhagic Shock Biomarker in a Rabbit Model. PLoS ONE, 2014, 9, e102285.	2.5	34

#	Article	IF	Citations
37	Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma. Journal of Molecular Histology, 2013, 44, 213-220.	2.2	14